Disease · EFO_0010682
Trials44
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 44
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00622869 | Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients | Phase 3 | 719 | 2013-05-20 | Liver Transplantation | EVEROLIMUS, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00086346 | Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients | Phase 3 | 607 | 2009-09-07 | Liver Transplantation | CYCLOSPORINE, SIROLIMUS, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01625377 | A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients | Phase 3 | 188 | 2016-04-27 | Liver Transplantation | EVEROLIMUS, MYCOPHENOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02115113 | REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy | Phase 3 | 78 | 2019-02-28 | Liver Transplantation | EVEROLIMUS, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00149890 | Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids | Phase 3 | 77 | 2011-09-22 | Liver Transplantation, Infection | BASILIXIMAB, CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov |
| NCT00336817 | A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients | Not applicable | 30 | 2017-03-09 | Immunosuppression | MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00282256 | A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients | Phase 2 | 19 | 2013-10-17 | Liver Transplantation | TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01230502 | Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation | Not applicable | 11 | 2014-05-07 | Liver Transplant | MYCOPHENOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT07157631 | Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial | Not applicable | 1,546 | Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD) | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT01011205 | Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation | Phase 3 | 893 | Liver Transplantation | BASILIXIMAB, MYCOPHENOLATE MOFETIL, TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT05707520 | Long-term Benefit of MPA in Liver Transplantation | 500 | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | MYCOPHENOLIC ACID | Its record names the disease | ClinicalTrials.gov | ||
| NCT00189826 | A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation. | Phase 3 | 475 | Liver Transplantation | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT02143479 | A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year | 398 | Liver Transplantation | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | ||
| NCT00451932 | A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients | Phase 2 | 303 | Liver Transplantation | MANITIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT04720326 | Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients | Phase 4 | 268 | Prophylaxis Against Liver Transplant Rejection | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT03603548 | Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial | Not applicable | 200 | Liver Transplant Rejection, Immunosuppression | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT00619398 | A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients | Phase 3 | 172 | Liver Transplantation | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT04069065 | Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL) | Phase 4 | 146 | Liver Transplant | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT01539057 | The Efficacy of the Administration of Fibrinogen in Liver Transplantation | Phase 3 | 132 | Intraoperative Bleeding | FIBRINOGEN, HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05744635 | Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients | 110 | Liver Failure | TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0010682/trials